Commentary on “Comparative efficacy and safety of PSCA CAR-engineered V{delta}1 {gamma}{delta} T cells for immunotherapy of pancreatic cancer”
Adoptive transfer of unmodified T cells has shown limited clinical benefit, prompting a shift toward chimeric antigen receptor (CAR) engineering to enhance activation, persistence, and tumor specificity. CAR technology positions T cells as promising…